Story
Never Stop Challenging Yourself
to Make GC Wellbeing
a Global Nutrition Solutions Company
Never stop challenging yourself to become a leading personalized nutrition solutions provider
Leap forward (2019-present)
- February 2021GC Wellbeing’s Laennec injection—COVID-19 treatment phase 2 clinical trial approved
- January 2021GC Wellbeing’s headquarters transferred from Sunaedong, Bundang-gu to the Parc 1 Tower in Yeouido (research center: Heungdeok U-Tower Knowledge Industry Center, Yongin)
- October 2020European clinical administration of “GCWB20,” a new cancer cachexia drug, completed
- September 2020Patent for compositions developed for the treatment of helicobacter infection registered
Patent for “probiotic strain” immune function enhanced Lactobacillus registered - July 2020Patent application for “NK Exosome” cosmetic composition
- June 2020Patent application for “antiviral composition” in Korea
- November 2019Patent acquired for kidney function improvement probiotic composition
Construction of the new facility in Chungbuk Innovation City - October 2019GC Wellbeing listed (KOSDAQ 234690)
- August 2019Patent acquired for the cosmetic composition of “NK Cell Culture Medium”
Expansion of Dr.PNT
In 2016, GC Wellbeing launched Dr. PNT, health supplements & foods for hospitals and clinics, and has expanded the solution to the treatment of pain, care of the intestines, and obesity.
Period of Growth (2016-2018)
- September 2018ISO 45001/ISO 14001 certified in Eumseong Plant
- August 2018Safety and health management system (ISO 45001) certification acquired
- December 2017GCWB204 German clinical trial phase-2 CTA approved
- November 2017Laennec IV clinical phase-3 IND approved
- April 2016Dr. PNT, a health supplements & foods for hospitals and clinics, launched
- March 2016Domestic patent registered for Lonicera japonica Thunb. (treatment of intestinal dyskinesia) completed
- February 2016BST204 (GCWB204) domestic patent registered (cancer-related fatigue)
Permit received for GCB bone injection
Permit received for GCB bone injection
Launch of GC Wellbeing Integrated Corporation
From 2006 to 2014, GC Wellbeing established PNT through a merger of GC JBP, which produces Laennec, a placental injection, GC Wellbeing Division, which sells non-covered injections, and Green Cross HS, which is in charge of research and development of natural materials and pharmaceuticals, ultimately laying the foundation to become a specialized company.
Formation Period (2015)
- December 2015Company name changed to GC Wellbeing
- October 2015Sales takeover of GC Wellbeing Division
Merger with GC HS Co., Ltd.
- March 2015Japanese PDMA GMP compliance inspection approved
Merger with GC HS Co., Ltd.
Expansion of nutritional injections for prescription drugs and development of new natural pharm products
From 2006 to 2014, each company that makes up the present GC Wellbeing grew into a leader in their respective fields on R&D, production, and sales.
Period of Exploration (2006-2014)
- November 2006JBPAcquired permission for using drug materials
- September 2014HSBST204 (GCWB204) phase-1 clinical trial in Germany completed
- May 2014GC6101A-gastritis and gastric ulcer IND approved in Korea
- April 2013Acquired license for food manufacturing
- February 2010Acquired license for health supplements & foods manufacturing
- July 2008Acquired license to manufacture food additives
Manufacturing of Prescription Drugs Based on Placenta
For the domestic production and supply of Laennec, a placental injection, GC Japan Bio was established in partnership with Japan Bio Products Co., Ltd. (JBP), laying the foundation for entering the “well-being injection market.” Considering the nature of human-derived medicines, which are vulnerable to contamination, Eumseong Plant, where Laennec is made, uses advanced manufacturing processes, including virus inactivation and sterilization confirmation, to ensure safe, stable production of high-quality products.